Summary
Synthetic peptides comprising the predicted principal neutralizing determinant (PND) in new African and North American HIV-1 clones were tested in ELISA for reactivity with ninety six serum samples from asymptomatic donors in six selected localities in Uganda. Irrespective of the geographical origin of the samples, the majority of the test sera cross-reacted at high intensities with the peptides derived from the novel North American clone, BRT3.6 (Group B), the Ugandan clone, CUG045, (Group C), and the Romanian clone, FRMA (Group F). The frequency of reactivity of the peptides from BRT3.6, CUG045, and FRMA were within the ranges of 57–100%, 50–100%, and 57–100%, respectively, for the sera collected from these disparate localities. In contrast to these findings, the V3 peptides derived from the other Ugandan isolates showed a more restricted pattern of reactivity with the same serum samples: AUG06c (1–63%), DUG23c (2%), and DUG044 (38–87%). The results from ELISA inhibition assay indicated that the V3 peptide from BRT 3.6, CUG045, and FRMA express closely related antigenic specificities quite distinct from those in AUG06c and DUG044. The residues comprising the PND in BRT 3.6, CUG045, and FRMA appear to be well conserved in the HIV-1 subtypes prevalent in the selected Ugandan locales.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
W.H.O. Network for HIV Isolation and Characterization. (1994) HIV Type 1 variation in World Health Organization-sponsored vaccine evaluation sites: genetic screening, sequence analysis and preliminary biological characterization of selected viral strains. AIDS Res Hum Retroviruses 10: 1327–1343
Wawer MJ, Serwadda D, Musgrave SD, Konde-Lule JK, Musagara M, Sewankambo N (1991) Dynamics of spread of HIV-1 infection in a rural district of Uganda. Br Med J 303: 1303–1306
Serwadda D, Wawer MJ, Musgrav SD, Kaplan JE, Gray RH (1992) HIV risk factors in three geographic strata of rural Rakai Distict, Uganda. AIDS 6: 983–989
Muller O, Barugahare L, Schwartlander B, Byaruhanga E, Kataaha P, Kyeyune D, Heckmann W, Ankrah M (1992) HIV prevalence attitudes and behavior in clients of a confidential HIV testing and counseling center in Uganda. AIDS 6: 869–874
Myers G, Wain-Hobson S, Korber B, Smith RF, Pavlakis GN (1993) Human retroviruses and AIDS: a compilation and analysis of nucleic acid and amino acid sequences. Los Alamos National Laboratory [December 1994 Supplement]
Janssens W, Heyndrick L, Van de Peer Y, Bouckaert A, Fransen K, Motte J, Gershy-Damet GM, Peeters M, Piot P, Van der Groen G (1994) Molecular phylogeny of part of the ENV gene of HIV-1 strains isolated in Cote d'Ivoire. AIDS 8: 21–26
Nkengasong JN, Janssens W, Heyndrickx L, Fransen K, Ndumbe PM, Motte J, Leonaers A, Ngolle M, Ayuk J, Piot P, van der Groen G (1984) Genotypic subtypes of HIV-1 in Cameroon. AIDS 8: 1405–1412
Pestano G, Hosford K, Spira A, Riley J, Sewankambo N, Brown L, Ho DD, Boto WMO (1995) Seroreactivity of analogous antigenic epitopes in gp 120 expressed in HIV-1 subtypes A, B, C and D. AIDS Res Hum Retroviruses 5: 589–596
Janssens W, Heyndrickx L, Kransen K, Motte J, Peeters M, Nikengasong JN, Ndumbe PM, Delaporte E, Peret JL, Atende C, Piot P, van der Groen G (1994) Genetic and phylogenetic analysis of ENV subtypes G and H in Central Africa. AIDS Res Hum Retroviruses 10: 877–879
Pestano G, Prince A, Guyden J, Ntambi J, Atkin A, Boto WO (1993) Independent divergencies in the CD4 binding site and V3 loop encoded in two seroprevalent Ugandan HIV-1 clinical isolates. J Acquir Immune Defic Syndr 6: 872–880
Riley JP, Pestano GA, Harewood K, Alfred LJ, Guyden J, Boto WMO (1995) Distribution of linear antigenic epitopes on gp120 encoded in sibling clones of novel New York HIV-1 subtype B isolates. Cell Mol Biol 41: 583–591
Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD (1993) Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 261: 1179–1181
Sanger F, Nicklen S, Coulson AR (1974) DNA sequencing with chain termination inhibitors. Proc Natl Acad Sci USA 74: 5463–5467
Javaherian K, Langlois AJ, McDanal C, Ross KL, Eckler LI, Jellis CL, Profy AT, Rusche JR, Bolognesi DP, Putney SD, Matthews TJ (1989) Principal neutralizing domain of the HIV-1 envelope protein. Proc Natl Acad Sci USA 86: 6768–6772
Lasky LA, Nakamura G, Smith DH, Fennie C, Shimasaki C, Patzer E, Berman P, Gregory T, Capon JD (1987) Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell 50: 975–985
Sudhir K, Koichiro T, Nei M (1993) MEGA: Molecular Evolutionary Genetics analysis, version 1.01. The Pennsylvania State University, University Park, PA 16802
Devereux J, Haeberly P, Smithies OA (1984) A comprehensive set of sequence analysis programs for the VAX. Nucleic Acids Res 12: 385–387
Parker JMR, Hodges RS (1991) Prediction of surface and interior regions in proteins — part 1: linear tripeptide sequences identify structural boundaries in proteins. Pept Res 4: 347–354
Merrifield R (1963) Solid-phase peptide. The synthesis of a tetrapeptide. J Am Chem Soc 85: 2149–2153
Boto WO, Powers KG, Levy DA (1984) Antigens of Dirofilaria immitis which are immunogenic in the canine host: detection by immunostaining of protein blots with the antibodies of occult dogs. J Immunol 133: 975–979
Dumitrescu O, Kalish M, Kliks SC, Bandea CI, Levy JA (1994) Characterization of HIV-1 strains isolated from children in Romania: identification of a new envelope subtype. J Infect Dis 169: 281–288
Modrow S, Hahn BH, Shaw GM, Gallo RC, Wong-Staal F, Wolf H (1987) Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions. J Virol 61: 570–578
Robinson WE Jr, Mitchell WM (1990) Neutralization and enhancement of in vitro and in vivo HIV and simian immunodeficiency virus infection. AIDS 4: S151–S162
Pau C-P, Kai M, Candal-Holloman DL, Luo-C-C, Kalish ML, Schochemtaman G, Byers B, George JR, The WHO Network for HIV Isolation and Characterization (1994) Antigenic variation and serotyping of HIV type 1 from four World Health Organization-Sponsored HIV vaccine sites. AIDS Res Hum Retroviruses 10: 1369–1377
Popov-Cheingsong R, Lister S, Collow D, Kaleebu P, Beddows S, Weber J, and the W.H.O. Network for HIV Isolation and Characterization (1994) Serotyping HIV type 1 by antibody binding to the V3 loop: Relationship to viral genotype. AIDS Res Hum Retroviruses 10: 1379–1386
Korber B, Maclnnes K, Smith RF, Myers G (1994) Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1. J Virol 68: 6730–6744
Carrow EW, Vujcic LK, Glass WL, Seamon KB, Rastogi SC, Hendry RM, Boulos R, Nzila M, Quinna GV Jr (1991) High prevalence of antibodies to the gp 120 V3 region principal neutralizing determinant of HIV-1 MN in the sera from Africa and the Americas. AIDS Res Hum Retroviruses 7: 831–838
Bailou A, Brand D, Francois D, M'Boup S, Chout R, Goudeau A, Barin F (1993) High antigenic cross-reactivity of the V3 consensus sequences of HIV-1 gp 120. AIDS Res Hum Retroviruses 9: 1209–1215
Laman JD, Schellekens MM, Abacuoglu YH, Lewis GK, Termette M, Fouchier RAM, Langedijk JPM, Classen E, Boersman WJA (1992) Variant-specific polyclonal HIV-1 neutralizing antibodies raised with synthetic peptides from the gp 120 third variable domain. J Virol 66: 1823–1831
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Riley, J.P., Pestano, G.A., Hosford, K. et al. Relative reactivity of the V3 loop PND of HIV-1 subtypes A, B, C, D, and F with sera from selected Ugandan localities. Archives of Virology 140, 1393–1404 (1995). https://doi.org/10.1007/BF01322666
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01322666